Efficacy and safety of RD2 Ver.02, a whole blood clot therapy, coupled with a minimally invasive procedure in pilonidal sinus: a phase II study.


Journal

Techniques in coloproctology
ISSN: 1128-045X
Titre abrégé: Tech Coloproctol
Pays: Italy
ID NLM: 9613614

Informations de publication

Date de publication:
13 Aug 2024
Historique:
received: 04 11 2023
accepted: 11 07 2024
medline: 13 8 2024
pubmed: 13 8 2024
entrez: 13 8 2024
Statut: epublish

Résumé

PNS is caused by an infection in the sacrococcygeal area triggered by hair particle accumulation in skin tunnels, resulting in infection. Surgical options range from simple excision to complex flap constructions. Primary wound healing failure and recurrence rates contribute to the burden of PNS. RD2 Ver.02, a novel autologous whole-blood clot product, demonstrated safety and efficacy in treating complex cutaneous wounds and was investigated for the management of PNS. A Phase II open-label, pilot, single-arm prospective study was conducted from May 2021 to May 2023 (Ethics Committee approval #7952-20). Patients with PNS underwent a minimally invasive trephine procedure under local anesthesia followed by RD2 Ver.02 instillation into the cavity. Primary healing was assessed at 3, 6, and 12 months. Secondary outcomes included the collection of adverse events. Overall, 51 patients participated in the study. At 3 months, 42/51 healed (82.4%), 7/51 (13.7%) were granulating but not completely healed, and 2/51 (3.9%) failed to heal. At 6 and 12 months, 46/51 (90.2%) and 42/51 (82.4%) achieved complete healing, respectively. At 6 months, two PNSs recurred after initial healing and an additional four instances of PNS recurrence observed in 12 months, so a total of recurrence in six patients (11.8%). There were five adverse events (AEs) with no severe adverse events. RD2 Ver.02 is a safe and effective treatment of PNS when coupled with a minimally invasive trephine PNS procedure. Further comparative studies are needed to fully assess the role of this novel therapy for PNS.

Sections du résumé

BACKGROUND BACKGROUND
PNS is caused by an infection in the sacrococcygeal area triggered by hair particle accumulation in skin tunnels, resulting in infection. Surgical options range from simple excision to complex flap constructions. Primary wound healing failure and recurrence rates contribute to the burden of PNS. RD2 Ver.02, a novel autologous whole-blood clot product, demonstrated safety and efficacy in treating complex cutaneous wounds and was investigated for the management of PNS.
METHODS METHODS
A Phase II open-label, pilot, single-arm prospective study was conducted from May 2021 to May 2023 (Ethics Committee approval #7952-20). Patients with PNS underwent a minimally invasive trephine procedure under local anesthesia followed by RD2 Ver.02 instillation into the cavity. Primary healing was assessed at 3, 6, and 12 months. Secondary outcomes included the collection of adverse events.
RESULTS RESULTS
Overall, 51 patients participated in the study. At 3 months, 42/51 healed (82.4%), 7/51 (13.7%) were granulating but not completely healed, and 2/51 (3.9%) failed to heal. At 6 and 12 months, 46/51 (90.2%) and 42/51 (82.4%) achieved complete healing, respectively. At 6 months, two PNSs recurred after initial healing and an additional four instances of PNS recurrence observed in 12 months, so a total of recurrence in six patients (11.8%). There were five adverse events (AEs) with no severe adverse events.
CONCLUSION CONCLUSIONS
RD2 Ver.02 is a safe and effective treatment of PNS when coupled with a minimally invasive trephine PNS procedure. Further comparative studies are needed to fully assess the role of this novel therapy for PNS.

Identifiants

pubmed: 39136828
doi: 10.1007/s10151-024-02973-9
pii: 10.1007/s10151-024-02973-9
doi:

Types de publication

Journal Article Clinical Trial, Phase II

Langues

eng

Sous-ensembles de citation

IM

Pagination

97

Informations de copyright

© 2024. Springer Nature Switzerland AG.

Références

Varnalidis I, Ioannidis O, Paraskevas G et al (2014) Pilonidal sinus: a comparative study of treatment methods. J Med Life 7(1):27
pubmed: 24653753 pmcid: 3956091
Hull TL, Wu J (2002) Pilonidal disease. Surg Clin N Am 82(6):1169–1185. https://doi.org/10.1016/S0039-6109(02)00062-2
doi: 10.1016/S0039-6109(02)00062-2 pubmed: 12516846
Luedi MM, Schober P, Stauffer VK, Diekmann M, Andereggen L, Doll D (2021) Gender-specific prevalence of pilonidal sinus disease over time: a systematic review and meta-analysis. ANZ J Surg 91(7–8):1582–1587
doi: 10.1111/ans.16990 pubmed: 34101331
Mahmood F, Hussain A, Akingboye A (2020) Pilonidal sinus disease: review of current practice and prospects for endoscopic treatment. Ann Med Surg 57:212–217. https://doi.org/10.1016/J.AMSU.2020.07.050
doi: 10.1016/J.AMSU.2020.07.050
Maione F, D’Amore A, Milone M, Vertaldi S, Anoldo P, Chini A, Sorrentino C, Marello A, Cantore G, Maione R, D’Angelo S, D’Alesio N, De Simone G, Servillo G, De Palma GD, Manigrasso M (2023) Endoscopic approach to complex or recurrent pilonidal sinus: a retrospective analysis. Int Wound J 20(4):1212–1218. https://doi.org/10.1111/iwj.13980 . (Epub 2022 Oct 21)
doi: 10.1111/iwj.13980 pubmed: 36271666
Milone M, Velotti N, Manigrasso M, Anoldo P, Milone F, de Palma GD (2018) Long-term follow-up for pilonidal sinus surgery: a review of literature with metanalysis. Surgeon 16(5):315–320. https://doi.org/10.1016/J.SURGE.2018.03.009
doi: 10.1016/J.SURGE.2018.03.009 pubmed: 29699781
Harries RL, Alqallaf A, Torkington J, Harding KG (2019) Management of sacrococcygeal pilonidal sinus disease. Int Wound J 16:370–378
doi: 10.1111/iwj.13042 pubmed: 30440104
McCallum I, King PM, Bruce J (2007) Healing by primary versus secondary intention after surgical treatment for pilonidal sinus. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD006213.PUB2/INFORMATION/EN
doi: 10.1002/14651858.CD006213.PUB2/INFORMATION/EN pubmed: 17943897
Stauffer VK, Luedi MM, Kauf P et al (2018) Common surgical procedures in pilonidal sinus disease: a meta-analysis, merged data analysis, and comprehensive study on recurrence. Sci Rep 8(1):3058. https://doi.org/10.1038/S41598-018-20143-4
doi: 10.1038/S41598-018-20143-4 pubmed: 29449548 pmcid: 5814421
Win M, Went TR, Ruo SW et al (2021) A systematic review of fibrin glue as an ideal treatment for the pilonidal disease. Cureus. https://doi.org/10.7759/CUREUS.16831
doi: 10.7759/CUREUS.16831 pubmed: 34646680 pmcid: 8485362
Herrod PJ, Doleman B, Hardy EJ et al (2022) Dressings and topical agents for the management of open wounds after surgical treatment for sacrococcygeal pilonidal sinus. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD013439.PUB2
doi: 10.1002/14651858.CD013439.PUB2 pubmed: 35593897 pmcid: 9121912
Emile SH, Elfeki H, Shalaby M et al (2018) Endoscopic pilonidal sinus treatment: a systematic review and meta-analysis. Surg Endosc 32(9):3754–3762. https://doi.org/10.1007/S00464-018-6157-5
doi: 10.1007/S00464-018-6157-5 pubmed: 29603009
Kalaiselvan R, Bathla S, Allen W, Liyanage A, Rajaganeshan R (2019) Minimally invasive techniques in the management of pilonidal disease. Int J Colorectal Dis 34(4):561–568. https://doi.org/10.1007/S00384-019-03260-Y
doi: 10.1007/S00384-019-03260-Y pubmed: 30810799
Meinero P, la Torre M, Lisi G et al (2019) Endoscopic pilonidal sinus treatment (EPSiT) in recurrent pilonidal disease: a prospective international multicenter study. Int J Colorectal Dis 34(4):741–746. https://doi.org/10.1007/S00384-019-03256-8
doi: 10.1007/S00384-019-03256-8 pubmed: 30719564
Tien T, Athem R, Arulampalam T (2018) Outcomes of endoscopic pilonidal sinus treatment (EPSiT): a systematic review. Tech Coloproctol 22(5):325–331. https://doi.org/10.1007/S10151-018-1803-4
doi: 10.1007/S10151-018-1803-4 pubmed: 29850944
Erculiani M, Mottadelli G, Carlini C, Barbetta V, Dusio MP, Pini PA (2022) Long-term results of EPSiT in children and adolescents: still the right way to go. Pediatr Surg Int 38(9):1257–1261. https://doi.org/10.1007/S00383-022-05162-7
doi: 10.1007/S00383-022-05162-7 pubmed: 35779104
Harris CL, Laforet K, Sibbald RG, Bishop R (2012) Twelve common mistakes in pilonidal sinus care. Adv Skin Wound Care 25(7):324–332. https://doi.org/10.1097/01.ASW.0000416004.70465.8A
doi: 10.1097/01.ASW.0000416004.70465.8A pubmed: 22713784
Rodrigues M, Kosaric N, Bonham CA, Gurtner GC (2019) Wound healing: a cellular perspective. Physiol Rev 99:665–706. https://doi.org/10.1152/physrev.00067.2017.-Wound
doi: 10.1152/physrev.00067.2017.-Wound pubmed: 30475656
Diller RB, Tabor AJ (2022) The role of the extracellular matrix (ECM) in wound healing: a review. Biomimetics 7(3):87. https://doi.org/10.3390/BIOMIMETICS7030087
doi: 10.3390/BIOMIMETICS7030087 pubmed: 35892357 pmcid: 9326521
Snyder RJ, Schultz G, Wachuku C, Rashid AM, Ead JKK (2020) Proposed mechanism of action of topically applied autologous blood clot tissue: a quintessential cellular and tissue based therapy. J Am Podiatr Med Assoc. https://doi.org/10.7547/20-140 . (Published online October 13, 2020)
doi: 10.7547/20-140
Serena TE, Kushnir I, Kushnir A, Yaakov RA, Eckert KA (2019) The safety of an autologous whole blood clot product applied to full thickness dermal wounds in a porcine model for up to 18 days. Chron Wound Care Manag Res. https://doi.org/10.2147/CWCMR.S189836 . (Published online 2019)
doi: 10.2147/CWCMR.S189836
Naude L, Idensohn P, Bruwer F et al (2021) An observational pilot study to collect safety and efficacy data on wound care using whole blood clot technology on hard-to-heal wounds. Wounds Int J 12(2). https://www.woundsinternational.com/journals/issue/644/article-details/observational-pilot-study-collect-safety-and-efficacy-data-wound-care-using-whole-blood-clot-technology-hard-heal-wounds . Accessed 17 Aug 2022
Kushnir I, Kushnir A, Serena T, Garfinkel D (2016) Efficacy and safety of a novel autologous wound matrix in the management of complicated, chronic wounds: a pilot study. Wounds 28(9). https://www.hmpgloballearningnetwork.com/site/wounds/article/efficacy-and-safety-novel-autologous-wound-matrix-management-complicated-chronic-wounds . Accessed 23 Aug 2022
Snyder R, Kasper M, Patel K et al (2018) Safety and efficacy of an autologous blood clot product in the management of Texas 1A or 2A neuropathic diabetic foot ulcers: a prospective, multicenter, open label pilot study. Wounds 30(7). https://www.hmpgloballearningnetwork.com/site/wounds/original-research/safety-and-efficacy-autologous-blood-clot-product-management-texas-1a . Accessed 23 Aug 2022
Gurevich M, Wahab N, Wachuku C, Ead KJ, Snyder RJ (2021) ActiGraft treatment in complex wounds with exposed structure—a case series. USA Ann Rev Res. https://doi.org/10.19080/ARR.2021.07.555701
doi: 10.19080/ARR.2021.07.555701
Williams M, Davidson D, Wahab N, Hawkins J, Wachuku CD, Snyder R (2022) Innovative treatment utilizing an autologous blood clot for diabetic foot ulcers. Wounds 34(7):195–200. https://doi.org/10.25270/WNDS/21089
doi: 10.25270/WNDS/21089 pubmed: 35881826
Landau Z, Whitacre KL, Leewood C, Hawkins J, Wachuku CD (2022) Utilization of a topical autologous blood clot for treatment of pressure ulcers. Int Wound J. https://doi.org/10.1111/IWJ.13927 . (Published online 2022)
doi: 10.1111/IWJ.13927 pubmed: 36054532 pmcid: 9927894
di Castro A, Guerra F, Levi Sandri GB, Ettorre GM (2016) Minimally invasive surgery for the treatment of pilonidal disease. The Gips procedure on 2347 patients. Int J Surg 36(Pt A):201–205. https://doi.org/10.1016/J.IJSU.2016.10.040
doi: 10.1016/J.IJSU.2016.10.040 pubmed: 27989917
Gips M, Melki Y, Salem L, Weil R, Sulkes J (2008) Minimal surgery for pilonidal disease using trephines: description of a new technique and long-term outcomes in 1,358 patients. Dis Colon Rectum 51(11):1656–1663. https://doi.org/10.1007/S10350-008-9329-X
doi: 10.1007/S10350-008-9329-X pubmed: 18516645
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf . Accessed 27 Nov 2017
Dimitriou E (2022) Chronic venus ulcer pain reduction and full recovery by an autologous blood clot: a case study. J Clin Images Med Case Rep. https://doi.org/10.52768/2766-7820/1714
doi: 10.52768/2766-7820/1714
Khalilieh S, Horesh N, Cordoba M, Forschmidt E, Zager Y, Nadler R, Gutman M, Rosin D, Ram E (2022) Surgical outcomes of minimally invasive trephine surgery for pilonidal sinus disease and risk factors for recurrence. J Laparoendosc Adv Surg Tech A 32(3):288–292. https://doi.org/10.1089/lap.2021.0097 . (Epub 2021 May)
doi: 10.1089/lap.2021.0097 pubmed: 33960849
Kanlioz M, Ekici U (2019) Complications during the recovery period after pilonidal sinus surgery. Cureus. https://doi.org/10.7759/CUREUS.4501
doi: 10.7759/CUREUS.4501 pubmed: 31938617 pmcid: 6946042
Bubenova M, Mittlboeck M, Kulinna-Cosentini C, Teleky B, Cosentini E (2022) Pilonidal sinus disease: a 25-year experience and long-term results of different surgical techniques. Eur Surg Acta Chirurg Austr 54(5):240–248. https://doi.org/10.1007/S10353-022-00767-7/TABLES/4
doi: 10.1007/S10353-022-00767-7/TABLES/4

Auteurs

E Ram (E)

Department of General Surgery B and Transplantation, Sheba Medical Hospital Center, Tel Hashomer, Ramat Gan, Israel.

Y Zager (Y)

Department of General Surgery B and Transplantation, Sheba Medical Hospital Center, Tel Hashomer, Ramat Gan, Israel.

D Carter (D)

Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.

R Anteby (R)

Department of Gastroenterology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.

J Haik (J)

Department of Plastic and Reconstructive Surgery, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.

I Nachmany (I)

Department of General Surgery B and Transplantation, Sheba Medical Hospital Center, Tel Hashomer, Ramat Gan, Israel.

N Horesh (N)

Department of General Surgery B and Transplantation, Sheba Medical Hospital Center, Tel Hashomer, Ramat Gan, Israel. nir_horesh@hotmail.com.
Department of Colorectal Surgery, Cleveland Clinic Florida, 2950 Cleveland Clinic Blvd., Weston, FL, 33331, USA. nir_horesh@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH